Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer

Nature Reviews Clinical Oncology

Volumn 6, Issue 6, 2009, Pages 308-309

  Castañeda, Carlos A ^a   Gomez, Henry L ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MUCOSA INFLAMMATION; MYALGIA; NEUROTOXICITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; SURVIVAL TIME; BREAST TUMOR; FEMALE; METABOLISM; NOTE; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; PACLITAXEL; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 68549121149     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.68     Document Type: Article

References (10)

1. Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Johnston, J. B. et al. Targeting the EGFR Pathway for Cancer Therapy. Curr. Medicinal Chem. 13, 3483-3492 (2006).
3. Jin, Q. & Esteva, F. J. Cross-talk between the erbB/HeR Family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 13, 485-498 (2008).
4. Gomez, H. L. et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J. Clin. Oncol. 26, 2999-3005 (2008).
5. Cameron, D. et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 10, 1007 (2008).
6. Herendeen, J. M. et al. An open label, fixed sequence, two period study to evaluate the potential induction of GW572016 metabolism by carbamazepine [Abstract]. ASCO Meeting Abstracts 22, 3081 (2004).
7. Beulz-Riche, D., Robert, J., Riché, C. & Ratanasavanh, D. effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes. Cancer Chemother. Pharmacol. 49, 274-280 (2002).
8. Jones, S. F. et al. A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009) [Abstract]. ASCO Meeting Abstracts 22, 2083 (2004).
9. Cristofanilli, M. et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [Abstract]. San Antonio Breast Cancer Symposium, 2006 December 14-17, San Antonio, TX.
10. Di Leo, A. et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J. Clin. Oncol. 26, 5544-5552 (2008).